Clinical trial registry record

Comparison between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration

A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered not applicable study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated August 24, 2016.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
ISRCTN86106799
Last registry update
August 24, 2016
Status
Completed
Phase
Not Applicable
Sponsor
The First Hospital of Qiqihar City
Enrollment
180
Countries
China
Match confidence
100%
Source feed
ISRCTN Registry
Automated source synopsis

A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Not Applicable
Study design
Interventional
Evidence population
Human clinical study registration
Participants
180
Population
All · Adult
Duration
2014-05-02 to 2016-05-01
Intervention
Conbercept, ranibizumab; Drug
Comparator
Not reported
Outcomes measured
Best-corrected visual acuity (BCVA), as determined using the ETDRS chart at one year; 1. The number of injections counted at the end of one year follow-up 2. Retinal thickness measured at every visit by OC…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Not ApplicableA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as Interventional.

Automated source check 98% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON